One approval, three things worth reading: what the product is, what the evidence was, and the letter that delayed it
The FDA approved the first treatment for pediatric patients with Sanfilippo syndrome type A.
The efficacy comparison was an untreated historical cohort, not a placebo arm.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf) on September 17, the first treatment for pediatric patients with MPS IIIA. It is a one-time intravenous gene therapy that uses an AAV9 vector to deliver a working copy of the SGSH gene. The FDA says effectiveness was evaluated in an open-label, single-arm study read against an untreated historical control cohort.
What was announced
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf) on September 17. It is the first treatment for pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The agency granted the approval to Ultragenyx Pharmaceutical, Inc.
MPS IIIA progressively damages the brain and nervous system. Children lose cognitive, language and other developmental abilities over time. Until this approval, treatment was limited to managing symptoms.
The first-in-disease label is the headline. For a program team, what the approval was built on and why it arrived a year later than first planned are the two facts that travel.
The approval, in short
- What was approved: Fayuvi (rebisufligene etisparvovec-hopf), for pediatric patients with MPS IIIA.
- Who holds it: Ultragenyx Pharmaceutical, Inc.
- How it is given: a one-time intravenous infusion of an AAV9 vector carrying a working copy of the SGSH gene.
- Pivotal evidence: an open-label, single-arm, multicenter study, read against an untreated historical control cohort.
- Designations: Orphan Drug, Fast Track and Breakthrough Therapy.
- Action date: NeurologyLive reports a PDUFA date of September 19, 2026, assigned after the resubmission was accepted on April 2, 2026.
What the approval rests on
The FDA says safety and effectiveness were evaluated in an open-label, single-arm, multicenter study. It measured mean changes in cognitive scores in patients between the ages of 2 and 5 years. Treated patients maintained or improved cognitive function compared to an untreated historical control cohort.
A concurrent placebo arm was never realistically on the table. MPS IIIA is progressive, the cognitive endpoint was measured in children aged 2 to 5, and randomising a child in that position to no treatment is not a design an ethics committee approves. The question worth taking from this approval is therefore not whether an external control was acceptable, but how much natural history the FDA needed before it was.
NeurologyLive reports that the approval drew on the Transpher A program (NCT02716246) and its long-term follow-up study (NCT04360265). It describes the package as biomarker and neurodevelopmental data, rather than a conventional randomized, placebo-controlled efficacy trial.
In 27 patients at the highest evaluated dose, 3 × 1013 vector genomes/kg, median CSF heparan sulfate fell 63.98% from baseline as of the September 2025 cutoff. Among that population, 81.5% reached at least a 50% reduction. Follow-up ran up to 8.5 years, with a median of 4.8 years.
Among 17 children treated earlier in the disease course, Fayuvi (then UX111) was associated with a 23.2-point treatment effect in mean Bayley-III cognitive raw score. The comparison was against natural history controls. Those children were assessed between 24 and 60 months of age.
A 23.2-point Bayley-III cognitive treatment effect against natural history controls, in children assessed between 24 and 60 months of age.
NeurologyLive calls CSF heparan sulfate reduction the primary biomarker supporting approval, and an intermediate end point. The FDA announcement leads instead with cognitive scores against the historical cohort. Both framings describe the same filing, and a team citing this precedent should carry both.
Neither source states whether this was a traditional or an accelerated approval, and the distinction decides how the filing can be cited. Under accelerated approval a biomarker endpoint carries a confirmatory-trial obligation; under a traditional approval it is supporting evidence sitting alongside the cognitive comparison. A team planning to lean on this precedent needs that answer from the approval letter, not from the press release.
Why the approval took until September 2026
NeurologyLive reports that the original BLA was accepted with priority review in February 2025, with an initial PDUFA date of August 18, 2025. In July 2025 the FDA issued a complete response letter. It cited chemistry, manufacturing and controls observations and requested additional long-term clinical data.
Ultragenyx resubmitted on January 30, 2026, adding another year of follow-up across multiple biomarker and clinical measures. The FDA accepted the resubmission on April 2, 2026 and set a new action date of September 19, 2026.
Fourteen months between the complete response letter and the approval.
How Fayuvi works, and how it is given
Fayuvi uses a modified, non-infectious AAV9 vector to deliver a working copy of the SGSH gene. That lets cells produce sulfamidase, the enzyme that is missing or deficient in MPS IIIA. Heparan sulfate can then be broken down in lysosomes.
It is administered in a healthcare setting equipped to manage infusion reactions. All patients receive corticosteroid treatment beginning one day before the infusion. That treatment continues for a minimum of eight weeks afterward.
The safety picture
The FDA lists increases in liver enzymes (AST), nausea and vomiting, and fever among the most common adverse reactions. Decreased appetite, decreased white blood cell and platelet counts, and increased amylase are also listed. All were reported in more than 5% of patients.
Important safety warnings include the risk of thrombotic microangiopathy. The FDA also notes a potential long-term risk that the inserted genetic material could integrate into the genome. It says that could lead to tumor development, as with other AAV-based gene therapies.
What this means for a CGT program
GTC analysis: on CMC, the letter came in July 2025 and the approval came in September 2026. Ultragenyx took six months to resubmit; the agency's handling of that resubmission accounted for the rest. The number to carry into a filing-readiness argument is fourteen months, not the six.
Fayuvi held Breakthrough Therapy designation throughout. It did not prevent a manufacturing-driven complete response letter, and it did not shorten the fourteen months that followed.
GTC analysis: on budget, what saved this filing was a follow-up study already running when the letter arrived. Ultragenyx had up to 8.5 years of it. A team that starts building that dataset after a complete response letter cannot buy the time back, and no consultant, including this one, can shorten it for them.
GTC analysis: on regulatory strategy, the pivotal comparison was an untreated historical control cohort, not a concurrent placebo arm. What decides whether that travels to another program is not the indication, it is how much documented natural history the agency required before accepting the comparison. Ultragenyx brought up to 8.5 years of its own follow-up to that question.
GTC analysis: on timeline, the approval landed September 17, two days before the assigned action date.
If you have taken a gene therapy through a CMC complete response letter, GTC's Expert Network matches CMC experts like you to paid consulting work: join free.
Frequently asked questions
What did the FDA approve on September 17, 2026?
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The FDA granted the approval to Ultragenyx Pharmaceutical. Before this approval, treatment was limited to managing symptoms, and there was no FDA-approved therapy designed to change the underlying course of the disease.
What evidence supported the approval?
The FDA says safety and effectiveness were evaluated in an open-label, single-arm, multicenter clinical study in pediatric patients with MPS IIIA. The study measured mean changes in cognitive scores in patients between the ages of 2 and 5 years. Treated patients maintained or improved cognitive function compared to an untreated historical control cohort. NeurologyLive reports that CSF heparan sulfate reduction served as the primary biomarker supporting approval, and describes it as an intermediate end point.
How does Fayuvi work, and how is it given?
Fayuvi is a one-time intravenous gene therapy that uses a modified, non-infectious AAV9 vector to deliver a working copy of the SGSH gene. That lets cells produce sulfamidase, the enzyme that is missing or deficient in MPS IIIA, so heparan sulfate can be broken down in lysosomes. It is given in a healthcare setting equipped to manage infusion reactions. All patients receive corticosteroid treatment beginning one day before the infusion. That treatment continues for a minimum of eight weeks afterward.
Why did the approval take until September 2026?
NeurologyLive reports that the original biologics license application was accepted with priority review in February 2025. The initial PDUFA action date was August 18, 2025. In July 2025 the FDA issued a complete response letter citing chemistry, manufacturing and controls observations and requesting additional long-term clinical data. Ultragenyx resubmitted on January 30, 2026 with an additional year of follow-up. The FDA accepted the resubmission on April 2, 2026 and set a new PDUFA action date of September 19, 2026.
What are the known safety risks?
The FDA lists increases in liver enzymes (AST), nausea and vomiting, and fever among the most common adverse reactions. Decreased appetite, decreased white blood cell and platelet counts, and increased amylase are also listed. All were reported in more than 5% of patients. Important safety warnings include the risk of thrombotic microangiopathy. As with other AAV-based gene therapies, the FDA notes a potential long-term risk. The inserted genetic material could integrate into the genome and lead to tumor development.
Sources
- FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A – U.S. Food and Drug Administration, press announcement, September 17, 2026.
- FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A – NeurologyLive, Marco Meglio, September 17, 2026.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.